Sponsor

Genesis Pharma S.A.

Greece Kifissias Leoforos 270, 152 32, Greece

About the sponsor

Research activity is centered on acute ischemic stroke, with attention to outcomes linked to hemorrhagic transformation and the clinical management of acute brain injury.

Acute ischemic stroke
Hemorrhagic transformation
Neurological emergency care

The sponsor’s current clinical work in this area reflects a focused interest in therapies relevant to cerebrovascular protection and acute neurology.

About Specializations

Genesis Pharma S.A. runs clinical trials in conditions such as Ischaemic stroke, among others.

Ischaemic stroke

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

1 clinical trial

Ischaemic stroke

Not yet recruiting

InvestigationalNo placebo

Study of Drug Combination with Amodiaquine and Potassium Canrenoate Plus Exenatide or Glibenclamide for Patients with Acute Ischemic Stroke

InvestigationalNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:AMODIAQUINE
Sponsor:Genesis Pharma S.A.

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →